179th Day Of Lockdown

Maharashtra114584081235431351 Andhra Pradesh6095585198915244 Tamil Nadu5309084757178685 Karnataka5029823940257808 Uttar Pradesh3362942632884771 Delhi2347011981034877 West Bengal2155801870614183 Odisha167161133466722 Telangana1670461353571016 Bihar164224149722855 Assam150349121610528 Kerala12221687341490 Gujarat119088999083271 Rajasthan109088906851293 Haryana103773816901069 Madhya Pradesh97906743981877 Punjab90032658182646 Chhatisgarh7777541111628 Jharkhand6710052807590 Jammu and Kashmir5971138521951 Uttarakhand3713924810460 Goa2678320844327 Puducherry2142816253431 Tripura2069612956222 Himachal Pradesh11190691997 Chandigarh92566062106 Manipur8430653951 Arunachal Pradesh6851496713 Nagaland5306407910 Meghalaya4356234232 Sikkim2119178923 Mizoram15069490
Nation Current Affairs 09 Sep 2020 AstraZeneca's C ...

AstraZeneca's COVID vaccine trials continue in India: Serum Institute

REUTERS
Published Sep 9, 2020, 4:25 pm IST
Updated Sep 10, 2020, 10:35 am IST
AstraZeneca said it has paused global trials, including large late-stage trials, due to an unexplained illness in a study participant
Serum Institute of India said that trials of AstraZeneca Plc’s COVID-19 vaccine candidate in the country is ongoing and has not faced any issues. (Representative Image)
 Serum Institute of India said that trials of AstraZeneca Plc’s COVID-19 vaccine candidate in the country is ongoing and has not faced any issues. (Representative Image)

Serum Institute of India said on Wednesday that trials of AstraZeneca Plc’s COVID-19 vaccine candidate in the country is ongoing and has not faced any issues.

AstraZeneca said it has paused global trials, including large late-stage trials, of its experimental coronavirus vaccine due to an unexplained illness in a study participant.

 

“We can’t comment much on the UK trials,” Serum Institute said in a statement, adding “as far as Indian trials are concerned, it is continuing and we have faced no issues at all.”

A spokesperson for the AstraZeneca vaccine said in a statement Tuesday that "we voluntarily paused vaccination to allow review of safety data by an independent committee. "This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials."

 

The company said that in large trials, illnesses will sometimes happen by chance but must be reviewed independently.

Pune-based vaccine maker earlier shortlisted 17 sites in India for the Phase II clinical trial of COVID-19 vaccine. At least 1,600 candidates aged between 18 to 55, will participate in the trial.

Each participant will administer two doses in a gap of four weeks. First dose will be given on day one and second dose will be scheduled on day 29," according to the study design by Serum Institute of India.

...




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT